

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10591048
	Filing Date		2007-03-28
	First Named Inventor	SCHLINGENSIEPEN	
	Art Unit	1637	
	Examiner Name	BENZION, Gary	
	Attorney Docket Number	4052.003	

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10591048
Filing Date	2007-03-28
First Named Inventor	SCHLINGENSIEPEN
Art Unit	1637
Examiner Name	BENZION, Gary
Attorney Docket Number	4052.003

1	NISHIZAKI T, et al.; "Genetic alterations in primary breast cancers and their metastases: direct comparison using modified comparative genomic hybridization"; Genes chromosomes cancer. 1997 Aug; 19 (4):267-72. ABSTRACT ONLY	<input type="checkbox"/>
2	LI, Sr, et al.; "Differential expression patterns of the insulin-like growth factor 2 gene in human colorectal cancer"; Tumour Biol. 2004 Jan-Apr; 25(1-2): 62-8. ABSTRACT ONLY	<input type="checkbox"/>
3	SMITH, Amanda Pfaff, et al.; "Whole-Genome Expression Profiling of the Melanoma Progression Pathway Reveals Marked Molecular Differences between Nevi/Melanoma In Situ and Advanced-Stage Melanomas"; Cancer Biology & therapy 4:9, 1018-1029, Sept. 2005.	<input type="checkbox"/>
4	UJHAZY, V. et al.; "Heterogeneity of tumor cells;" Antibiot Chemother. 1980; 28:120-2. ABSTRACT ONLY	<input type="checkbox"/>
5	MONTEL, Valerie, et al; "Expression Profiling of Primary Tumors and Matched Lymphatic and Lung Metastases in a Xenogeneic Breast Cancer Model;" Am. J. of Path., Vol. 166, No. 5, May 2005; pp. 1565-1579.	<input type="checkbox"/>
6	MESSICK, C.A., et al.; "Stage III colorectal cancer: molecular disparity between primary cancers and lymph node metastases;" Ann Surg Oncol. 2010 Feb; 17(2):425-31. Epub 2009 Nov. 3. ABSTRACT ONLY	<input type="checkbox"/>
7	POPLAWSKI, A.B., et al.; "Frequent genetic differences between matched primary and metastatic breast cancer provide an approach to identification of biomarkers for disease progression;" Eur J Hum Genet. 2010 May; 18 (5):560-8. Epub 2010 Jan 6. ABSTRACT ONLY	<input type="checkbox"/>
8	Schlingensiepen et al., "TGF-beta2 Gene Silencing with Trabedersen (AP 12009) in Pancreatic Cancer;" pgs. 1-24, unpublished manuscript	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.